Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25117761 | 1.00 | HPGD (0.40) | HPGDCYP3A4CYP2C19RAB9AEPHX1 | |
| SCHEMBL2454893 | 0.84 | HPGD (0.40) | HPGDCYP3A4CYP2C19RAB9AEPHX1 | |
| SCHEMBL2450674 | 0.84 | HPGD (0.39) | HPGDCYP3A4CYP2C19RAB9AEPHX1 | |
| SCHEMBL5907681 | 0.84 | HPGD (0.53) | HPGDCYP3A4CYP2C19RAB9AEPHX1 | |
| SCHEMBL23119122 | 0.82 | EPHX1 (0.46) | HPGDEPHX1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL25117766 | 0.82 | EPHX1 (0.46) | HPGDEPHX1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL23081207 | 0.81 | HPGD (0.42) | HPGDCYP3A4CYP2C19RAB9AEPHX1 | |
| SCHEMBL23081097 | 0.81 | HPGD (0.42) | HPGDCYP3A4CYP2C19RAB9AEPHX1 | |
| SCHEMBL25444132 | 0.81 | HPGD (0.42) | HPGDCYP3A4CYP2C19RAB9AEPHX1 | |
| SCHEMBL25444545 | 0.81 | HPGD (0.42) | HPGDCYP3A4CYP2C19RAB9AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | HPGD 2196/4885CYP3A4 1662/4885CYP2C19 1232/4885 |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | HPGD 2196/4885CYP3A4 1662/4885CYP2C19 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.